{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:24:23Z","timestamp":1794428663786,"version":"4.9.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["H2023109"],"award-info":[{"award-number":["H2023109"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["SJCX24_1532"],"award-info":[{"award-number":["SJCX24_1532"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["XZSYSKF2020037"],"award-info":[{"award-number":["XZSYSKF2020037"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.beha.2025.101639","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T19:10:30Z","timestamp":1748459430000},"page":"101639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in NK cell therapy for multiple myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Najing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuoxian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinge","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2025.101639_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2025.101639_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2025.101639_bib3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.beha.2025.101639_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020226","article-title":"Alterations of NK cell phenotype in the disease course of multiple myeloma","volume":"13","author":"Pazina","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.beha.2025.101639_bib5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/JLB.5MR0920-198RR","article-title":"Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy","volume":"109","author":"Devillier","year":"2021","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.beha.2025.101639_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109168","article-title":"NK cell therapy in relapsed refractory multiple myeloma","volume":"246","author":"Roshandel","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.beha.2025.101639_bib7","first-page":"107","article-title":"Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. VI. Metasarcolysin","volume":"21","author":"Austin","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.beha.2025.101639_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib9","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib10","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib11","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101639_bib12","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib14","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112261","article-title":"Future directions in maintenance therapy in multiple myeloma","volume":"10","author":"Holstein","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.beha.2025.101639_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112712","article-title":"Rapid progress in immunotherapies for multiple myeloma: an updated comprehensive review","volume":"13","author":"Nishida","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.beha.2025.101639_bib17","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1599636","article-title":"Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells","volume":"8","author":"Ochoa","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.beha.2025.101639_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.15433","article-title":"Infectious and immunological sequelae of daratumumab in multiple myeloma","volume":"185","author":"Johnsrud","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2025.101639_bib20","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2025.101639_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.13046","article-title":"Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis","volume":"100","author":"Pick","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2025.101639_bib22","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2025.101639_bib24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/bloodadvances.2024014717","article-title":"Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma","volume":"9","author":"Yee","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101639_bib26","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2025.101639_bib27","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","article-title":"Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial","volume":"12","author":"Askeland","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2025.101639_bib28","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(24)00320-X","article-title":"Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial","volume":"12","author":"Mina","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2025.101639_bib29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s12967-025-06543-x","article-title":"Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed\/refractory multiple myeloma","volume":"23","author":"An","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.beha.2025.101639_bib30","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101639_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib32","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib33","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101639_bib34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101639_bib35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2025.101639_bib36","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","article-title":"Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial","volume":"10","author":"Li","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beha.2025.101639_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.beha.2025.101639_bib38","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2025.101639_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.beha.2025.101639_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","article-title":"Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering","volume":"51","author":"Daher","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.beha.2025.101639_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.beha.2025.101639_bib42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101639_bib43","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.beha.2025.101639_bib44","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/eji.202049028","article-title":"Human NK cells, their receptors and function","volume":"51","author":"Quatrini","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.beha.2025.101639_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.beha.2025.101639_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing cancer immunotherapies that engage T cells and NK cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.beha.2025.101639_bib47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.beha.2025.101639_bib48","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12185-022-03365-1","article-title":"Novel immunotherapies in multiple myeloma","volume":"115","author":"Ohmine","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.beha.2025.101639_bib49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing natural killer cells for the treatment of multiple myeloma","volume":"49","author":"Clara","year":"2022","journal-title":"Semin Oncol"},{"key":"10.1016\/j.beha.2025.101639_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/bloodadvances.2022007985","article-title":"Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15","volume":"7","author":"Fernandez","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101639_bib51","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/ejh.13839","article-title":"The evolution of immune dysfunction in multiple myeloma","volume":"109","author":"Soekojo","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2025.101639_bib52","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beha.2025.101639_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030392","article-title":"Harnessing the potential of NK cell-based immunotherapies against multiple myeloma","volume":"11","author":"Reina-Ortiz","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.beha.2025.101639_bib54","first-page":"351","article-title":"Next-Generation therapies for multiple myeloma","volume":"8","author":"Meermeier","year":"2024","journal-title":"Annu Rev Cell Biol"},{"key":"10.1016\/j.beha.2025.101639_bib55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s40164-024-00578-4","article-title":"Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities","volume":"13","author":"Bisht","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.beha.2025.101639_bib56","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4149\/neo_2018_171019N668","article-title":"Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy","volume":"65","author":"Chang","year":"2018","journal-title":"Neoplasma"},{"key":"10.1016\/j.beha.2025.101639_bib57","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2025.101639_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002866","article-title":"NK cells enhance CAR-T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving CAR-T cell fitness","volume":"9","author":"Bachiller","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.beha.2025.101639_bib59","doi-asserted-by":"crossref","first-page":"89256","DOI":"10.18632\/oncotarget.19204","article-title":"A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy","volume":"8","author":"Williams","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.beha.2025.101639_bib60","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2022016205","article-title":"Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies","volume":"141","author":"Cichocki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101639_bib61","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.stem.2021.08.013","article-title":"Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy","volume":"28","author":"Woan","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.beha.2025.101639_bib62","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1038\/s41467-022-35127-2","article-title":"Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma","volume":"13","author":"Cichocki","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.beha.2025.101639_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.707542","article-title":"CAR-NK cells: from natural basis to design for kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101639_bib64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-023-01435-3","article-title":"CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022","volume":"16","author":"Huang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.beha.2025.101639_bib65","first-page":"763","article-title":"Challenges in \u03b1CD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide","volume":"25","author":"Karvouni","year":"2023","journal-title":"Cytopathology (Oxf)"},{"key":"10.1016\/j.beha.2025.101639_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12010248","article-title":"CAR NK92 cells targeting BCMA can effectively kill multiple myeloma cells both in vitro and in vivo","volume":"12","author":"Park","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.beha.2025.101639_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1533044","article-title":"Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression","volume":"16","author":"Jo","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101639_bib68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40164-023-00461-8","article-title":"Single VHH-directed BCMA CAR-NK cells for multiple myeloma","volume":"12","author":"Ren","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.beha.2025.101639_bib69","first-page":"1","article-title":"Novel approaches of cellular therapy in multiple myeloma: focus on chimeric antigen receptor T-cells","author":"Narra","year":"2024","journal-title":"Acta Haematol"},{"key":"10.1016\/j.beha.2025.101639_bib70","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1172\/JCI90387","article-title":"CD56bright NK cells exhibit potent antitumor responses following IL-15 priming","volume":"127","author":"Wagner","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.beha.2025.101639_bib71","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/1078-0432.CCR-15-1419","article-title":"The IL-15-based ALT-803 complex enhances Fc\u03b3RIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas","volume":"22","author":"Rosario","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2025.101639_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002024","article-title":"NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy","volume":"9","author":"Miyazaki","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.beha.2025.101639_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1368290","article-title":"Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence","volume":"15","author":"van Hees","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101639_bib74","first-page":"350","article-title":"Efficacy of chimeric antigen receptor engineered natural killer cells in the treatment of hematologic malignancies: a systematic review and meta-analysis of preclinical studies","volume":"27","author":"Bastin","year":"2025","journal-title":"Cytopathology (Oxf)"},{"key":"10.1016\/j.beha.2025.101639_bib75","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00262-021-02982-9","article-title":"Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21","volume":"71","author":"Thangaraj","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.beha.2025.101639_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.beha.2025.101639_bib77","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1016\/j.beha.2025.101639_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jimmun\/vkae004","article-title":"Memory-like NK cell differentiation, inhibitory NKG2A blockade, and improved recognition via antibody or CAR engineering combine to enhance NK cell attack against multiple myeloma","volume":"214","author":"Zhou","year":"2025","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2025.101639_bib79","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","article-title":"CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model","volume":"29","author":"Ng","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.beha.2025.101639_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383136","article-title":"CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma","volume":"15","author":"Moles","year":"2024","journal-title":"Front Immunol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:51:29Z","timestamp":1757094689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1521692625000441"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101639","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in NK cell therapy for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101639"}}